Literature DB >> 30615497

A role for phosphatidylcholine and phosphatidylethanolamine in hepatic insulin signaling.

Jelske N van der Veen1,2, Susanne Lingrell1,2, Nicholas McCloskey3, Nicholas D LeBlond3, Danny Galleguillos1,4, Yuan Y Zhao5, Jonathan M Curtis5, Simonetta Sipione1,4, Morgan D Fullerton3, Dennis E Vance1,2, René L Jacobs1,5.   

Abstract

Phosphatidylethanolamine N-methyltransferase (PEMT) is an important enzyme in hepatic phosphatidylcholine (PC) biosynthesis. Pemt-/- mice fed a high-fat diet are protected from obesity and whole-body insulin resistance. However, Pemt-/- mice develop severe nonalcoholic steatohepatitis (NASH). Because NASH is often associated with hepatic insulin resistance, we investigated whether the increased insulin sensitivity in Pemt-/- mice was restricted to nonhepatic tissues or whether the liver was also insulin sensitive. Strikingly, the livers of Pemt-/- mice compared with those of Pemt+/+ mice were not insulin resistant, despite elevated levels of hepatic triacylglycerols and diacylglycerols, as well as increased hepatic inflammation and fibrosis. Endogenous glucose production was lower in Pemt-/- mice under both basal and hyperinsulinemic conditions. Experiments in primary hepatocytes and hepatoma cells revealed improved insulin signaling in the absence of PEMT, which was not due to changes in diacylglycerols, ceramides, or gangliosides. On the other hand, the phospholipid composition in hepatocytes seems critically important for insulin signaling such that lowering the PC:phosphatidylethanolamine (PE) ratio improves insulin signaling. Thus, treatments to reduce the PC:PE ratio in liver may protect against the development of hepatic insulin resistance.-Van der Veen, J. N., Lingrell, S., McCloskey, N., LeBlond, N. D., Galleguillos, D., Zhao, Y. Y., Curtis, J. M., Sipione, S., Fullerton, M. D., Vance, D. E., Jacobs, R. L. A role for phosphatidylcholine and phosphatidylethanolamine in hepatic insulin signaling.

Entities:  

Keywords:  PEMT; fatty liver disease; insulin resistance; lipids; phospholipid

Mesh:

Substances:

Year:  2019        PMID: 30615497     DOI: 10.1096/fj.201802117R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  10 in total

1.  Distinct Lipidomic Signatures in People Living With HIV: Combined Analysis of ACTG 5260s and MACS/WIHS.

Authors:  Jennifer Jao; Lauren C Balmert; Shan Sun; Grace A McComsey; Todd T Brown; Phyllis C Tien; Judith S Currier; James H Stein; Yunping Qiu; Derek LeRoith; Irwin J Kurland
Journal:  J Clin Endocrinol Metab       Date:  2022-01-01       Impact factor: 6.134

2.  Transcriptome and metabolome changes induced by bitter melon (Momordica charantia)- intake in a high-fat diet induced obesity model.

Authors:  Dominique Reed; Dileep Kumar; Sushil Kumar; Komal Raina; Reenu Punia; Rama Kant; Laura Saba; Charmion Cruickshank-Quinn; Boris Tabakoff; Nichole Reisdorph; Michael G Edwards; Michael Wempe; Chapla Agarwal; Rajesh Agarwal
Journal:  J Tradit Complement Med       Date:  2021-08-19

3.  High-fat diet-induced upregulation of exosomal phosphatidylcholine contributes to insulin resistance.

Authors:  Anil Kumar; Kumaran Sundaram; Jingyao Mu; Gerald W Dryden; Mukesh K Sriwastva; Chao Lei; Lifeng Zhang; Xiaolan Qiu; Fangyi Xu; Jun Yan; Xiang Zhang; Juw Won Park; Michael L Merchant; Henry C L Bohler; Baomei Wang; Shuangqin Zhang; Chao Qin; Ziying Xu; Xianlin Han; Craig J McClain; Yun Teng; Huang-Ge Zhang
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

4.  The Treatment With the SGLT2 Inhibitor Empagliflozin Modifies the Hepatic Metabolome of Male Zucker Diabetic Fatty Rats Towards a Protective Profile.

Authors:  Alana Aragón-Herrera; Manuel Otero-Santiago; Laura Anido-Varela; Sandra Moraña-Fernández; Manuel Campos-Toimil; Tomás García-Caballero; Luis Barral; Estefanía Tarazón; Esther Roselló-Lletí; Manuel Portolés; Oreste Gualillo; Isabel Moscoso; Ricardo Lage; José Ramón González-Juanatey; Sandra Feijóo-Bandín; Francisca Lago
Journal:  Front Pharmacol       Date:  2022-02-02       Impact factor: 5.810

5.  Hepatic PTEN Signaling Regulates Systemic Metabolic Homeostasis through Hepatokines-Mediated Liver-to-Peripheral Organs Crosstalk.

Authors:  Flavien Berthou; Cyril Sobolewski; Daniel Abegg; Margot Fournier; Christine Maeder; Dobrochna Dolicka; Marta Correia de Sousa; Alexander Adibekian; Michelangelo Foti
Journal:  Int J Mol Sci       Date:  2022-04-02       Impact factor: 5.923

6.  Effect of Refining Degree on the Quality Changes and Lipid Oxidation of Camellia (Camellia oleifera) Oil during Heating.

Authors:  Mei Wang; Yin Wan; Ting Liu; Xiuying Zeng; Xinmei Liang; Xiaojiang Wu; Guiming Fu
Journal:  Foods       Date:  2022-07-27

7.  Phosphatidylethanolamine N-Methyltransferase Knockout Modulates Metabolic Changes in Aging Mice.

Authors:  Qishun Zhou; Fangrong Zhang; Jakob Kerbl-Knapp; Melanie Korbelius; Katharina Barbara Kuentzel; Nemanja Vujić; Alena Akhmetshina; Gerd Hörl; Margret Paar; Ernst Steyrer; Dagmar Kratky; Tobias Madl
Journal:  Biomolecules       Date:  2022-09-09

8.  Metabolomic Links between Sugar-Sweetened Beverage Intake and Obesity.

Authors:  Bingjie Zhou; Reiko Ichikawa; Laurence D Parnell; Sabrina E Noel; Xiyuan Zhang; Shilpa N Bhupathiraju; Caren E Smith; Katherine L Tucker; Jose M Ordovas; Chao-Qiang Lai
Journal:  J Obes       Date:  2020-04-13

9.  Ablation of Hmgb1 in Intestinal Epithelial Cells Causes Intestinal Lipid Accumulation and Reduces NASH in Mice.

Authors:  Harriet Gaskell; Xiaodong Ge; Romain Desert; Sukanta Das; Hui Han; Daniel Lantvit; Grace Guzman; Natalia Nieto
Journal:  Hepatol Commun       Date:  2019-11-12

10.  Pcyt2 deficiency causes age-dependant development of nonalcoholic steatohepatitis and insulin resistance that could be attenuated with phosphoethanolamine.

Authors:  Sophie Grapentine; Rathnesh K Singh; Poulami Basu; Sugashan Sivanesan; Gabriela Mattos; Oreoluwa Oresajo; Jasmine Cheema; Wendwesen Demeke; Vernon W Dolinsky; Marica Bakovic
Journal:  Sci Rep       Date:  2022-01-20       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.